{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:08:24Z","timestamp":1792624104026,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["201906170033"],"award-info":[{"award-number":["201906170033"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Remdesivir (GS-5734; VEKLURY) is a single diastereomer monophosphoramidate prodrug of an adenosine analog (GS-441524). Remdesivir is taken up by target cells and metabolized in multiple steps to form the active nucleoside triphosphate (GS-443902), which acts as a potent inhibitor of viral RNA-dependent RNA polymerases. Remdesivir and GS-441524 have antiviral activity against multiple RNA viruses. Here, we expand the evaluation of remdesivir\u2019s antiviral activity to members of the families <jats:italic>Flaviviridae<\/jats:italic>, <jats:italic>Picornaviridae<\/jats:italic>, <jats:italic>Filoviridae<\/jats:italic>, <jats:italic>Orthomyxoviridae<\/jats:italic>, and <jats:italic>Hepadnaviridae.<\/jats:italic> Using cell-based assays, we show that remdesivir can inhibit infection of flaviviruses (such as dengue 1\u20134, West Nile, yellow fever, Zika viruses), picornaviruses (such as enterovirus and rhinovirus), and filoviruses (such as various Ebola, Marburg, and Sudan virus isolates, including novel geographic isolates), but is ineffective or is significantly less effective against orthomyxoviruses (influenza A and B viruses), or hepadnaviruses B, D, and E. In addition, remdesivir shows no antagonistic effect when combined with favipiravir, another broadly acting antiviral nucleoside analog, and has minimal interaction with a panel of concomitant medications. Our data further support remdesivir as a broad-spectrum antiviral agent that has the potential to address multiple unmet medical needs, including those related to antiviral pandemic preparedness.\n<\/jats:p>","DOI":"10.1038\/s41598-023-29517-9","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:03:18Z","timestamp":1677150198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro"],"prefix":"10.1038","volume":"13","author":[{"given":"Sheli R.","family":"Radoshitzky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J. F.","family":"Kaptein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly S.","family":"Stuthman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean A.","family":"Van Tongeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapurna A.","family":"Sapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Jun","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijuan J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey M.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josolyn","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Shornikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cowfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle P.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"29517_CR1","doi-asserted-by":"publisher","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","volume":"9","author":"TP Sheahan","year":"2017","unstructured":"Sheahan, T. P. et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. 9, eaal3653. https:\/\/doi.org\/10.1126\/scitranslmed.aal3653 (2017).","journal-title":"Sci. Transl. Med."},{"key":"29517_CR2","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini, M. L. et al. Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221-00218. https:\/\/doi.org\/10.1128\/mBio.00221-18 (2018).","journal-title":"mBio"},{"key":"29517_CR3","doi-asserted-by":"publisher","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","volume":"32","author":"AJ Pruijssers","year":"2020","unstructured":"Pruijssers, A. J. et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 32, 107940 (2020).","journal-title":"Cell Rep."},{"key":"29517_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222. https:\/\/doi.org\/10.1038\/s41467-019-13940-6 (2020).","journal-title":"Nat. Commun."},{"key":"29517_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb5883 (2020).","journal-title":"Sci. Transl. Med."},{"key":"29517_CR6","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1038\/s41467-020-19055-7","volume":"11","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat. Commun. 11, 5214. https:\/\/doi.org\/10.1038\/s41467-020-19055-7 (2020).","journal-title":"Nat. Commun."},{"key":"29517_CR7","doi-asserted-by":"publisher","first-page":"109450","DOI":"10.1016\/j.celrep.2021.109450","volume":"36","author":"DR Martinez","year":"2021","unstructured":"Martinez, D. R. et al. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Rep. 36, 109450. https:\/\/doi.org\/10.1016\/j.celrep.2021.109450 (2021).","journal-title":"Cell Rep."},{"key":"29517_CR8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3389\/fmicb.2020.01105","volume":"11","author":"W Ye","year":"2020","unstructured":"Ye, W. et al. Remdesivir (GS-5734) impedes enterovirus replication through viral RNA synthesis inhibition. Front. Microbiol. 11, 1105. https:\/\/doi.org\/10.3389\/fmicb.2020.01105 (2020).","journal-title":"Front. Microbiol."},{"key":"29517_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa290","author":"DP Porter","year":"2020","unstructured":"Porter, D. P. et al. Remdesivir (GS-5734) is efficacious in cynomolgus macaques infected with Marburg virus. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiaa290 (2020).","journal-title":"J. Infect. Dis."},{"key":"29517_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385. https:\/\/doi.org\/10.1038\/nature17180 (2016).","journal-title":"Nature"},{"key":"29517_CR11","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","volume":"60","author":"D Siegel","year":"2017","unstructured":"Siegel, D. et al. Discovery and synthesis of a phosphoramidate prodrug of a Pyrrolo [2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J. Med. Chem. 60, 1648\u20131661. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01594 (2017).","journal-title":"J. Med. Chem."},{"key":"29517_CR12","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1021\/acs.jmedchem.1c00071","volume":"64","author":"RL Mackman","year":"2021","unstructured":"Mackman, R. L. et al. Prodrugs of a 1\u2019-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside leading to the discovery of Remdesivir (GS-5734) as a potent inhibitor of respiratory syncytial virus with efficacy in the African green monkey model of RSV. J. Med. Chem. 64, 5001\u20135017. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00071 (2021).","journal-title":"J. Med. Chem."},{"key":"29517_CR13","doi-asserted-by":"publisher","first-page":"43395","DOI":"10.1038\/srep43395","volume":"7","author":"MK Lo","year":"2017","unstructured":"Lo, M. K. et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 7, 43395. https:\/\/doi.org\/10.1038\/srep43395 (2017).","journal-title":"Sci. Rep."},{"key":"29517_CR14","doi-asserted-by":"publisher","first-page":"eaau9242","DOI":"10.1126\/scitranslmed.aau9242","volume":"11","author":"MK Lo","year":"2019","unstructured":"Lo, M. K. et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci. Transl. Med. 11, eaau9242. https:\/\/doi.org\/10.1126\/scitranslmed.aau9242 (2019).","journal-title":"Sci. Transl. Med."},{"key":"29517_CR15","doi-asserted-by":"publisher","first-page":"101529","DOI":"10.1016\/j.jbc.2021.101529","volume":"298","author":"CJ Gordon","year":"2022","unstructured":"Gordon, C. J. et al. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. J. Biol. Chem. 298, 101529. https:\/\/doi.org\/10.1016\/j.jbc.2021.101529 (2022).","journal-title":"J. Biol. Chem."},{"key":"29517_CR16","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","volume":"169","author":"AJ Brown","year":"2019","unstructured":"Brown, A. J. et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir. Res. 169, 104541. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104541 (2019).","journal-title":"Antivir. Res."},{"key":"29517_CR17","doi-asserted-by":"publisher","first-page":"706901","DOI":"10.3389\/fphar.2021.706901","volume":"12","author":"HY Hsu","year":"2021","unstructured":"Hsu, H. Y. et al. Remdesivir and cyclosporine synergistically inhibit the human coronaviruses OC43 and SARS-CoV-2. Front. Pharmacol. 12, 706901. https:\/\/doi.org\/10.3389\/fphar.2021.706901 (2021).","journal-title":"Front. Pharmacol."},{"key":"29517_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3181\/00379727-121-30734","volume":"121","author":"D Hamre","year":"1966","unstructured":"Hamre, D. & Procknow, J. J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 121, 190\u2013193. https:\/\/doi.org\/10.3181\/00379727-121-30734 (1966).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"29517_CR19","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.bmcl.2012.02.105","volume":"22","author":"A Cho","year":"2012","unstructured":"Cho, A. et al. Synthesis and antiviral activity of a series of 1\u2019-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorg. Med. Chem. Lett. 22, 2705\u20132707. https:\/\/doi.org\/10.1016\/j.bmcl.2012.02.105 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"29517_CR20","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1038\/s41598-021-98971-0","volume":"11","author":"TK Warren","year":"2021","unstructured":"Warren, T. K. et al. Remdesivir is efficacious in rhesus monkeys exposed to aerosolized Ebola virus. Sci. Rep. 11, 19458. https:\/\/doi.org\/10.1038\/s41598-021-98971-0 (2021).","journal-title":"Sci. Rep."},{"key":"29517_CR21","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3390\/v13102010","volume":"13","author":"BF Beitzel","year":"2021","unstructured":"Beitzel, B. F. et al. On-demand patient-specific phenotype-to-genotype Ebola virus characterization. Viruses 13, 2010. https:\/\/doi.org\/10.3390\/v13102010 (2021).","journal-title":"Viruses"},{"key":"29517_CR22","doi-asserted-by":"publisher","first-page":"104592","DOI":"10.1016\/j.antiviral.2019.104592","volume":"171","author":"A Pessi","year":"2019","unstructured":"Pessi, A. et al. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo. Antivir. Res. 171, 104592. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104592 (2019).","journal-title":"Antivir. Res."},{"key":"29517_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","volume":"82","author":"Y Furuta","year":"2009","unstructured":"Furuta, Y. et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antivir. Res. 82, 95\u2013102. https:\/\/doi.org\/10.1016\/j.antiviral.2009.02.198 (2009).","journal-title":"Antivir. Res."},{"key":"29517_CR24","doi-asserted-by":"publisher","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","volume":"8","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl. Trop. Dis. 8, e2804. https:\/\/doi.org\/10.1371\/journal.pntd.0002804 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"29517_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/14787210.2015.1018183","volume":"13","author":"MG Ison","year":"2015","unstructured":"Ison, M. G. Optimizing antiviral therapy for influenza: Understanding the evidence. Expert Rev. Anti. Infect. Ther. 13, 417\u2013425. https:\/\/doi.org\/10.1586\/14787210.2015.1018183 (2015).","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"29517_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.coviro.2016.05.004","volume":"18","author":"HL Yen","year":"2016","unstructured":"Yen, H. L. Current and novel antiviral strategies for influenza infection. Curr. Opin. Virol. 18, 126\u2013134. https:\/\/doi.org\/10.1016\/j.coviro.2016.05.004 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"29517_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s40262-015-0364-1","volume":"55","author":"V Madelain","year":"2016","unstructured":"Madelain, V. et al. Ebola virus infection: Review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin. Pharmacokinet. 55, 907\u2013923. https:\/\/doi.org\/10.1007\/s40262-015-0364-1 (2016).","journal-title":"Clin. Pharmacokinet."},{"key":"29517_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/cpt.1844","volume":"108","author":"YX Du","year":"2020","unstructured":"Du, Y. X. & Chen, X. P. Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin. Pharmacol. Ther. 108, 242\u2013247. https:\/\/doi.org\/10.1002\/cpt.1844 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"29517_CR29","doi-asserted-by":"publisher","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","volume":"11","author":"TH Nguyen","year":"2017","unstructured":"Nguyen, T. H. et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis. 11, e0005389. https:\/\/doi.org\/10.1371\/journal.pntd.0005389 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"29517_CR30","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739-743. https:\/\/doi.org\/10.1093\/nar\/gkac382 (2022).","journal-title":"Nucleic Acids Res."},{"key":"29517_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.anthro.27.1.247","volume":"27","author":"R Barrett","year":"1998","unstructured":"Barrett, R., Kuzawa, C. W., McDade, T. & Armelagos, G. J. Emerging and Re-emerging infectious diseases: The third epidemiologic transition. Annu. Rev. Anthropol. 27, 247\u2013271 (1998).","journal-title":"Annu. Rev. Anthropol."},{"key":"29517_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3201\/eid0101.950101","volume":"1","author":"D Satcher","year":"1995","unstructured":"Satcher, D. Emerging infections: Getting ahead of the curve. Emerg. Infect. Dis. 1, 1\u20136. https:\/\/doi.org\/10.3201\/eid0101.950101 (1995).","journal-title":"Emerg. Infect. Dis."},{"key":"29517_CR33","unstructured":"GOV.UK. (2019)."},{"key":"29517_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4155\/fmc-2020-0134","volume":"13","author":"VV Kleandrova","year":"2021","unstructured":"Kleandrova, V. V. & Speck-Planche, A. The urgent need for pan-antiviral agents: From multitarget discovery to multiscale design. Future Med. Chem. 13, 5\u20138 (2021).","journal-title":"Future Med. Chem."},{"key":"29517_CR35","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.3390\/molecules27123815","volume":"27","author":"B Wang","year":"2022","unstructured":"Wang, B., Svetlov, D., Bartikofsky, D., Wobus, C. E. & Artsimovitch, I. Going retro, going viral: Experiences and lessons in drug discovery from COVID-19. Molecules 27, 3815 (2022).","journal-title":"Molecules"},{"key":"29517_CR36","doi-asserted-by":"publisher","first-page":"e0010220","DOI":"10.1371\/journal.pntd.0010220","volume":"16","author":"MR Hickman","year":"2022","unstructured":"Hickman, M. R., Saunders, D. L., Bigger, C. A., Kane, C. D. & Iversen, P. L. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Negl. Trop. Dis. 16, e0010220. https:\/\/doi.org\/10.1371\/journal.pntd.0010220 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"29517_CR37","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-020-01378-w","volume":"80","author":"YN Lamb","year":"2020","unstructured":"Lamb, Y. N. Remdesivir: First approval. Drugs 80, 1355\u20131363. https:\/\/doi.org\/10.1007\/s40265-020-01378-w (2020).","journal-title":"Drugs"},{"key":"29517_CR38","unstructured":"VEKLURY & Gilead Sciences Inc. (2022)."},{"key":"29517_CR39","doi-asserted-by":"publisher","first-page":"6415","DOI":"10.1038\/s41467-021-26760-4","volume":"12","author":"RM Cox","year":"2021","unstructured":"Cox, R. M. et al. Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nat. Commun. 12, 6415. https:\/\/doi.org\/10.1038\/s41467-021-26760-4 (2021).","journal-title":"Nat. Commun."},{"key":"29517_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm3410","author":"A Schafer","year":"2022","unstructured":"Schafer, A. et al. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abm3410 (2022).","journal-title":"Sci. Transl. Med."},{"key":"29517_CR41","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1128\/AAC.00289-10","volume":"54","author":"M Robinson","year":"2010","unstructured":"Robinson, M. et al. Novel HCV reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob. Agents Chemother. 54, 3099\u20133106. https:\/\/doi.org\/10.1128\/AAC.00289-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29517_CR42","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1080\/22221751.2020.1829994","volume":"9","author":"C Baker","year":"2020","unstructured":"Baker, C. et al. Identifying optimal capsid duplication length for the stability of reporter flaviviruses. Emerg. Microbes Infect. 9, 2256\u20132265. https:\/\/doi.org\/10.1080\/22221751.2020.1829994 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"29517_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1099\/0022-1317-82-6-1283","volume":"82","author":"HJG Tolou","year":"2001","unstructured":"Tolou, H. J. G. et al. Evidence for recombination in natural populations of dengue virus type 1 based on the analysis of complete genome sequences. J. Gen. Virol. 82, 1283\u20131290. https:\/\/doi.org\/10.1099\/0022-1317-82-6-1283 (2001).","journal-title":"J. Gen. Virol."},{"key":"29517_CR44","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0042-6822(90)90037-r","volume":"176","author":"K Osatomi","year":"1990","unstructured":"Osatomi, K. & Sumiyoshi, H. Complete nucleotide sequence of dengue type 3 virus genome RNA. Virology 176, 643\u2013647. https:\/\/doi.org\/10.1016\/0042-6822(90)90037-r (1990).","journal-title":"Virology"},{"key":"29517_CR45","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.antiviral.2013.01.011","volume":"98","author":"T De Burghgraeve","year":"2013","unstructured":"De Burghgraeve, T. et al. 3\u2019,5\u2019Di-O-trityluridine inhibits in vitro flavivirus replication. Antivir. Res. 98, 242\u2013247. https:\/\/doi.org\/10.1016\/j.antiviral.2013.01.011 (2013).","journal-title":"Antivir. Res."},{"key":"29517_CR46","doi-asserted-by":"publisher","first-page":"e0004695","DOI":"10.1371\/journal.pntd.0004695","volume":"10","author":"J Zmurko","year":"2016","unstructured":"Zmurko, J. et al. The viral polymerase inhibitor 7-Deaza-2\u2019-C-Methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model. PLoS Negl. Trop. Dis. 10, e0004695. https:\/\/doi.org\/10.1371\/journal.pntd.0004695 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"29517_CR47","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1128\/AAC.00686-10","volume":"54","author":"SJ Kaptein","year":"2010","unstructured":"Kaptein, S. J. et al. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue and yellow fever virus replication in vitro. Antimicrob. Agents Chemother. 54, 5269\u20135280. https:\/\/doi.org\/10.1128\/AAC.00686-10 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"29517_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chom.2016.05.004","volume":"19","author":"C Shan","year":"2016","unstructured":"Shan, C. et al. An infectious cDNA Clone of Zika virus to study viral virulence, mosquito transmission, and antiviral inhibitors. Cell Host Microbe 19, 891\u2013900. https:\/\/doi.org\/10.1016\/j.chom.2016.05.004 (2016).","journal-title":"Cell Host Microbe"},{"key":"29517_CR49","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","volume":"146","author":"Y Ni","year":"2014","unstructured":"Ni, Y. et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 146, 1070\u20131083. https:\/\/doi.org\/10.1053\/j.gastro.2013.12.024 (2014).","journal-title":"Gastroenterology"},{"key":"29517_CR50","doi-asserted-by":"publisher","first-page":"e0169648","DOI":"10.1371\/journal.pone.0169648","volume":"12","author":"C Niu","year":"2017","unstructured":"Niu, C. et al. The Smc5\/6 complex restricts HBV when localized to ND10 without inducing an innate immune response and is counteracted by the HBV X protein shortly after infection. PLoS ONE 12, e0169648. https:\/\/doi.org\/10.1371\/journal.pone.0169648 (2017).","journal-title":"PLoS ONE"},{"key":"29517_CR51","doi-asserted-by":"publisher","first-page":"10021","DOI":"10.1038\/s41598-019-46493-1","volume":"9","author":"Y Ni","year":"2019","unstructured":"Ni, Y. et al. Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus. Sci. Rep. 9, 10021. https:\/\/doi.org\/10.1038\/s41598-019-46493-1 (2019).","journal-title":"Sci. Rep."},{"key":"29517_CR52","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/s41467-019-10211-2","volume":"10","author":"FA Lempp","year":"2019","unstructured":"Lempp, F. A. et al. Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation. Nat. Commun. 10, 2265. https:\/\/doi.org\/10.1038\/s41467-019-10211-2 (2019).","journal-title":"Nat. Commun."},{"key":"29517_CR53","first-page":"93","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum, M. C. What is synergy?. Pharmacol. Rev. 41, 93\u2013141 (1989).","journal-title":"Pharmacol. Rev."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29517-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29517-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T11:06:24Z","timestamp":1677150384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-29517-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["29517"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-29517-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"16 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"XL, RG, HT, AAS, HY, XX, JJC, ZJS, SML, JC, AS, DC, HY, TC, DPP, JPB and JYF possess potential competing interests and the remaining authors do not have any competing interests. XZ received funding of the China Scholarship Council (Grant No.201906170033). This article reflects the views of the authors and should not be construed to represent the FDA\u2019s views or policies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3131"}}